{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:41:47Z","timestamp":1788777707863,"version":"build-2803163510"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109378","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:25:20Z","timestamp":1774110320000},"page":"109378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1668-8559","authenticated-orcid":false,"given":"Gerrina","family":"Ruiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-3997","authenticated-orcid":false,"given":"Ross A.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-1543","authenticated-orcid":false,"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lungcan.2026.109378_b0005","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-2600(23)00133-9","article-title":"Advances in lung cancer: a ground-breaking decade","volume":"11","author":"Stone","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109378_b0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0015","doi-asserted-by":"crossref","first-page":"506","DOI":"10.21037\/tlcr.2020.03.40","article-title":"Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival","volume":"10","author":"Casal-Mourino","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109378_b0020","doi-asserted-by":"crossref","first-page":"461","DOI":"10.21037\/tlcr.2019.08.05","article-title":"Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study)","volume":"8","author":"Provencio","year":"2019","journal-title":"Transl Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109378_b0025","unstructured":"National Cancer Institute. Surveillance, epidemiology, and end results program. 2025. https:\/\/seer.cancer.gov\/. Accessed August 13, 2025."},{"key":"10.1016\/j.lungcan.2026.109378_b0030","doi-asserted-by":"crossref","unstructured":"J. N\u00fctzinger, J. Bum Lee, J. Li Low, P. Ling Chia, S. Talisa Wijaya, B. Chul Cho, et al., Management of HER2 alterations in non-small cell lung cancer - the past, present, and future, Lung Cancer. 186 (2023) 107385, doi:10.1016\/j.lungcan.2023.107385.","DOI":"10.1016\/j.lungcan.2023.107385"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109378_b0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tcb.2006.10.008","article-title":"ErbB receptors: new insights on mechanisms and biology","volume":"16","author":"Linggi","year":"2006","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.lungcan.2026.109378_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102520","article-title":"Targeting HER2 alterations in non-small cell lung cancer: therapeutic breakthrough and challenges","volume":"114","author":"Yu","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107992","article-title":"Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: results from LC-SCRUM-Asia","volume":"197","author":"Kato","year":"2024","journal-title":"Lung Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109378_b0055","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70272","article-title":"Real-world prevalence, treatment patterns, and outcomes for patients with HER2 (ERBB2)-mutant metastatic non-small cell lung cancer, from a US-based clinico-genomic database","volume":"13","author":"Waliany","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2026.109378_b0060","unstructured":"C.M. Lovely, C. Baik, M. Nagasaka, T. Patil, S.S. Maruti, S. Stanhope, et al., Real-world patient characteristics, mutational landscape and outcomes in advanced\/metastatic HER2-mutant lung cancer, Submitted JCO Prec Oncol."},{"issue":"18","key":"10.1016\/j.lungcan.2026.109378_b0065","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109378_b0070","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: a report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0075","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cllc.2021.08.012","article-title":"The effects of HER2 alterations in EGFR mutant non-small cell lung cancer","volume":"23","author":"Nagasaka","year":"2022","journal-title":"Clin. Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109378_b0080","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/1759-7714.13419","article-title":"Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer","volume":"11","author":"Wei","year":"2020","journal-title":"Thorac. Cancer."},{"key":"10.1016\/j.lungcan.2026.109378_b0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2021.02.022","article-title":"Targeting rare and non-canonical driver variants in NSCLC - an uncharted clinical field","volume":"154","author":"Volckmar","year":"2021","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/his.14311","article-title":"Histological characteristics of lung adenocarcinoma with uncommon actionable alterations: special emphasis on MET exon 14 skipping alterations","volume":"78","author":"Hayashi","year":"2021","journal-title":"Histopath"},{"issue":"8","key":"10.1016\/j.lungcan.2026.109378_b0095","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/1878-0261.12733","article-title":"Clinical and molecular characteristics of chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations","volume":"14","author":"Fan","year":"2020","journal-title":"Mol. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109378_b0100","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109378_b0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109378_b0115","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"#cr-split#-10.1016\/j.lungcan.2026.109378_b0120.1","doi-asserted-by":"crossref","unstructured":"I.A. Jaiyesimi, N.B. Leighl, N. Ismaila, K. Alluri, N. Florez, S. Gadgeel, et al., Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3, J. Clin. Oncol. 42","DOI":"10.1200\/JCO.23.02746"},{"key":"#cr-split#-10.1016\/j.lungcan.2026.109378_b0120.2","doi-asserted-by":"crossref","unstructured":"(11) (2024) e1-e22, doi:10.1200\/JCO.23.02744.","DOI":"10.1200\/JCO.23.02744"},{"key":"10.1016\/j.lungcan.2026.109378_b0125","doi-asserted-by":"crossref","unstructured":"G.J. Riely, D.E. Wood, D.S. Ettinger, D.L. Aisner, W. Akerley, J.R. Bauman, et al., Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology, J. Natl. Compr. Canc. Netw. 22 (4) (2024) 249\u2013274, doi:10.6004\/jnccn.2204.0023.","DOI":"10.6004\/jnccn.2204.0023"},{"issue":"31","key":"10.1016\/j.lungcan.2026.109378_b0130","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109378_b0140","unstructured":"U.S. Food and Drug Administration. HERNEXEOS\u00ae. Prescribing information. Boehringer Ingelheim, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219042s000lbl.pdf . Accessed August 13, 2025."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109378_b0145","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0150","doi-asserted-by":"crossref","unstructured":"J. van Berge Henegouwen, M. Jebbink, L. Hoes, H. van der Wijngaart, L. Zeverijn, D. van der Velden, et al., 1261P Trastuzumab\/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: results of a DRUP trial cohort, Ann. Oncol. 32 (2021) S989, doi:10.1016\/j.annonc.2021.08.1864.","DOI":"10.1016\/j.annonc.2021.08.1864"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0155","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.21.01455","article-title":"Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: results from the IFCT-1703 R2D2 trial","volume":"40","author":"Mazieres","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35780","article-title":"Targeting HER2 in lung cancers: evolving treatment landscape and drug development strategies","volume":"131","author":"Reinhorn","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109378_b0165","doi-asserted-by":"crossref","unstructured":"R.K. Tawfiq, G.S. de Camargo Correia, S. Li, Y. Zhao, Y. Lou, R. Manochakian, Targeting lung cancer with precision: the ADC therapeutic revolution, Curr. Oncol. Rep. 27 (6) (2025) 669\u2013686, doi:10.1007\/s11912-025-01655-5.","DOI":"10.1007\/s11912-025-01655-5"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0170","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12967-025-06589-x","article-title":"Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2026.109378_b0175","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.021","article-title":"Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations","volume":"162","author":"Iwama","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"24","key":"10.1016\/j.lungcan.2026.109378_b0180","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109378_b0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0190","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109378_b0195","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.43107","article-title":"Trastuzumab deruxtecan for ERBB2-mutant metastatic non-small cell lung cancer with or without brain metastases: a secondary analysis of randomized clinical trials","volume":"8","author":"J\u00e4nne","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109378_b0200","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2026.109378_b0205","unstructured":"U.S. Food and Drug Administration. ENHERTU\u00ae. Prescribing information. Daiichi Sankyo, 2024. https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Enhertu&inline=true. Accessed March 03, 2025."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109378_b0210","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0215","doi-asserted-by":"crossref","unstructured":"A. Italiano, B. Besse, H. Borghaei, S. Popat, G.A. Palacios, A. Goncalves, et al., 118MO Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study, Immuno-Oncol. Techn. 24 (S) 100747, doi:10.1016\/j.iotech.2024.100747.","DOI":"10.1016\/j.iotech.2024.100747"},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0220","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s10555-024-10231-5","article-title":"Influence of antibody-drug conjugate cleavability, drug-to-antibody ratio, and free payload concentration on systemic toxicities: a systematic review and meta-analysis","volume":"44","author":"Tang","year":"2024","journal-title":"Cancer Metastasis Rev."},{"issue":"8_Supplement","key":"10.1016\/j.lungcan.2026.109378_b0230","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-LB031","article-title":"Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109378_b0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0240","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.lungcan.2026.109378_b0245","article-title":"Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2026.109378_b0250","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2021.39.15_suppl.1038","article-title":"Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: results from two phase 1 clinical trials","volume":"39","author":"Hurvitz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0255","doi-asserted-by":"crossref","unstructured":"B. Li, L. Gandhi, B. Besse, K. Jhaveri, J. Mazi\u00e8res, V. Boni, et al., FP14.15 neratinib-based combination therapy in HER2-mutant lung adenocarcinomas: findings from two international phase 2 studies, J. Thorac. Oncol. 16 (3) (2021) S234, doi:10.1016\/j.jtho.2021.01.158.","DOI":"10.1016\/j.jtho.2021.01.158"},{"issue":"7691","key":"10.1016\/j.lungcan.2026.109378_b0260","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2026.109378_b0265","doi-asserted-by":"crossref","unstructured":"L. Gandhi, B. Besse, J. Mazieres, S. Waqar, A. Cortot, F. Barlesi, et al., MA04.02 Neratinib \u00b1 temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study, J. Thorac. Oncol. 12 (1) (2017) S358\u2013S359, doi:10.1016\/j.jtho.2016.11.398.","DOI":"10.1016\/j.jtho.2016.11.398"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0270","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","article-title":"Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma","volume":"88","author":"De Greve","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109378_b0280","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","article-title":"Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)","volume":"14","author":"Dziadziuszko","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0285","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2020.07.017","article-title":"Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: a phase II trial","volume":"147","author":"Fan","year":"2020","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109378_b0290","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11523-022-00884-z","article-title":"A phase 2 trial of afatinib in patients with solid tumors that harbor genomic aberrations in the HER family: the MOBILITY3 basket study","volume":"17","author":"Salawu","year":"2022","journal-title":"Target. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109378_b0295","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.21037\/tcr.2020.03.10","article-title":"EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"9","author":"Wang","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0300","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.21.01113","article-title":"Poziotinib for patients with HER2 exon 20 mutant non-small-cell lung cancer: results from a phase II trial","volume":"40","author":"Elamin","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0305","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0310","unstructured":"U.S. Food and Drug Administration. September 22-23, 2022: Meeting of the Oncologic Drugs Advisory Committee Announcement. https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/september-22-23-2022-meeting-oncologic-drugs-advisory-committee-announcement-09222022. Accessed August 13, 2025."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109378_b0315","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/annonc\/mdy542","article-title":"HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib","volume":"30","author":"Wang","year":"2019","journal-title":"Ann. Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2026.109378_b0320","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study","volume":"38","author":"Zhou","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0325","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12916-022-02245-z","article-title":"Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial","volume":"20","author":"Song","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109378_b0330","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12916-022-02470-6","article-title":"Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)","volume":"20","author":"Yang","year":"2022","journal-title":"BMC Med."},{"key":"10.1016\/j.lungcan.2026.109378_b0335","doi-asserted-by":"crossref","unstructured":"F. Siegel, G. Karsli-Uzunbas, K. Kotynkova, Q. McVeigh, S. Siegel, D. Korr, et al., Abstract 4035: Preclinical activity of BAY 2927088 in HER2 mutant non-small cell lung cancer, Cancer Res. 83 (7_Supplement) (2023) 4035, doi:10.1158\/1538-7445.Am2023-4035.","DOI":"10.1158\/1538-7445.AM2023-4035"},{"key":"10.1016\/j.lungcan.2026.109378_b0340","doi-asserted-by":"crossref","unstructured":"G.K. Uzunbas, Q. McVeigh, A. Gupta, S. Hoyt, A. Cherniack, F. Siegel, et al., Abstract 433: Mechanisms of resistance to BAY 2927088, the first reversible inhibitor targeting EGFR exon 20 insertion mutations in non-small cell lung cancer, Cancer Res. 83 (7_Supplement) (2023) 433, doi:10.1158\/1538-7445.Am2023-433.","DOI":"10.1158\/1538-7445.AM2023-433"},{"key":"10.1016\/j.lungcan.2026.109378_b0345","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(22)00827-9","article-title":"BAY 2927088: the first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC","volume":"174","author":"Siegel","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109378_b0350","doi-asserted-by":"crossref","first-page":"S761","DOI":"10.1016\/j.annonc.2023.09.2409","article-title":"1320MO Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088","volume":"34","author":"Loong","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109378_b0355","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","author":"Le","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109378_b0360","unstructured":"U.S. Food and Drug Administration. HYRNUO\u00ae. Prescribing information. Bayer HealthCare Pharmaceuticals Inc., 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219972s000lblCorrected.pdf. Accessed December 10, 2025."},{"key":"10.1016\/j.lungcan.2026.109378_b0365","series-title":"SOHO-02: phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2-activating mutations","author":"Le","year":"2025"},{"issue":"7","key":"10.1016\/j.lungcan.2026.109378_b0370","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s43018-022-00412-y","article-title":"Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling","volume":"3","author":"Wilding","year":"2022","journal-title":"Nat. Cancer."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109378_b0375","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109378_b0380","doi-asserted-by":"crossref","first-page":"LB270","DOI":"10.1158\/1538-7445.AM2025-LB270","article-title":"Abstract LB270: absorption, distribution, metabolism and excretion (ADME) properties and absolute bioavailability of zongertinib, a selective oral HER2-specific tyrosine kinase inhibitor, in healthy male subjects","volume":"85","author":"Joseph","year":"2025","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.lungcan.2026.109378_b0385","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109378_b0390","doi-asserted-by":"crossref","unstructured":"G. Ruiter, E.F. Smit, R.A. Soo, N. Girard, D. Planchard, M.-J. Ahn, et al., PT2.12.03 Zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1. Presented at the World Conference of Lung Cancer (WCLC) 2025, Sept 6-9, Barcelona, Spain. Available https:\/\/cattendee.abstractsonline.com\/meeting\/21151\/presentation\/2231.","DOI":"10.1016\/j.jtho.2025.09.1159"},{"key":"10.1016\/j.lungcan.2026.109378_b0395","doi-asserted-by":"crossref","unstructured":"M. Aujay, A.J. Broad, S.D. Gross, L. Ren, J.P. Lyssikatos, S. Kintz, et al., Abstract 4019: Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignancies, Cancer Res. 83 (7_Supplement) (2023) 4019, doi:10.1158\/1538-7445.AM2023-4019.","DOI":"10.1158\/1538-7445.AM2023-4019"},{"key":"10.1016\/j.lungcan.2026.109378_b0400","first-page":"2025","volume":"08","author":"Waldron","year":"2025","journal-title":"Fierce Biotech. Kinase Inhibitor Biotech Enliven Calls Time on Phase 1 HER2 Solid Tumor Program"},{"key":"10.1016\/j.lungcan.2026.109378_b0405","doi-asserted-by":"crossref","unstructured":"Y. Sun, K.L. Andrews, A. Tangpeerachaikul, T.M. Nguyen, B. Gerard, N.E. Kohl, et al., Abstract 1979: Preclinical characterization of NVL-330, a selective and brain penetrant HER2 tyrosine kinase inhibitor with broad activity on HER2 oncogenic alterations, Cancer Res. 84 (6_Supplement) (2024) 1979, doi:10.1158\/1538-7445.AM2024-1979.","DOI":"10.1158\/1538-7445.AM2024-1979"},{"key":"10.1016\/j.lungcan.2026.109378_b0410","series-title":"NVL-330, a selective HER2 tyrosine kinase inhibitor, in patients with advanced or metastatic HER2-altered non-small cell lung cancer: the phase 1 HEROEX-1 study","author":"Le","year":"2025"},{"key":"10.1016\/j.lungcan.2026.109378_b0415","doi-asserted-by":"crossref","unstructured":"E.F. Smit, E. Felip, D. Uprety, M. Nagasaka, K. Nakagawa, L. Paz-Ares Rodriguez, et al., Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial, Lancet Oncol. 25 (4) (2024) 439\u2013454, doi:10.1016\/S1470-2045(24)00064-0.","DOI":"10.1016\/S1470-2045(24)00064-0"},{"issue":"9","key":"10.1016\/j.lungcan.2026.109378_b0420","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jtho.2020.05.002","article-title":"The International Association for the Study of Lung Cancer Global Survey on molecular testing in lung cancer","volume":"15","author":"Smeltzer","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109378_b0425","first-page":"255","article-title":"Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States","volume":"28","author":"Zhang","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:23:15Z","timestamp":1782663795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":86,"alternative-id":["S0169500226004393"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109378","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109378"}}